RBC Capital Initiates Coverage On Lexeo Therapeutics with Outperform Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has initiated coverage on Lexeo Therapeutics (NASDAQ:LXEO) with an Outperform rating and set a price target of $22.

November 28, 2023 | 11:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has initiated coverage on Lexeo Therapeutics with an Outperform rating and a price target of $22.
The initiation of coverage by RBC Capital with an Outperform rating typically indicates a positive outlook on the stock, suggesting that the analyst believes LXEO will perform well in the market. The announcement of a price target of $22, which is likely above the current trading price, suggests an expectation of growth and could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100